These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 34968676)

  • 1. Pharmacotherapy in familial hypercholesterolemia - Current state and emerging paradigms.
    Kallapur A; Sallam T
    Trends Cardiovasc Med; 2023 Apr; 33(3):170-179. PubMed ID: 34968676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of lomitapide on cardiovascular outcome measures in homozygous familial hypercholesterolemia: A modelling analysis.
    Leipold R; Raal F; Ishak J; Hovingh K; Phillips H
    Eur J Prev Cardiol; 2017 Nov; 24(17):1843-1850. PubMed ID: 28925748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Editorial commentary: Exciting new therapies for familial hypercholesterolemia, but we can also make better use of some old ones.
    Walsh JP
    Trends Cardiovasc Med; 2023 Apr; 33(3):180-181. PubMed ID: 35091044
    [No Abstract]   [Full Text] [Related]  

  • 4. Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia.
    Bell DA; Hooper AJ; Watts GF; Burnett JR
    Vasc Health Risk Manag; 2012; 8():651-9. PubMed ID: 23226021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and Safety of Lipid-Lowering Drug Treatments in Japanese Patients with Familial Hypercholesterolemia: Familial Hypercholesterolemia Expert Forum (FAME) Study.
    Yamashita S; Masuda D; Harada-Shiba M; Arai H; Bujo H; Ishibashi S; Daida H; Koga N; Oikawa S
    J Atheroscler Thromb; 2022 May; 29(5):608-638. PubMed ID: 33980760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Familial hypercholesterolemia treatments: Guidelines and new therapies.
    Raal FJ; Hovingh GK; Catapano AL
    Atherosclerosis; 2018 Oct; 277():483-492. PubMed ID: 30270089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The treatment of heterozygous familial hypercholesterolemia - a local perspective.
    Bułdak Ł
    Endokrynol Pol; 2021; 72(3):189-190. PubMed ID: 34292576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Familial Hypercholesterolemia: A Narrative Review on Diagnosis and Management Strategies for Children and Adolescents.
    Tada H; Takamura M; Kawashiri MA
    Vasc Health Risk Manag; 2021; 17():59-67. PubMed ID: 33628029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Familial hypercholesterolemia: current treatment and advances in management.
    Huijgen R; Vissers MN; Defesche JC; Lansberg PJ; Kastelein JJ; Hutten BA
    Expert Rev Cardiovasc Ther; 2008 Apr; 6(4):567-81. PubMed ID: 18402545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Balancing Low-density Lipoprotein Cholesterol Reduction and Hepatotoxicity With Lomitapide Mesylate and Mipomersen in Patients With Homozygous Familial Hypercholesterolemia.
    Won JI; Zhang J; Tecson KM; McCullough PA
    Rev Cardiovasc Med; 2017; 18(1):21-28. PubMed ID: 28509890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.
    Miname MH; Santos RD
    Prog Cardiovasc Dis; 2019; 62(5):414-422. PubMed ID: 31669498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LDL-cholesterol target achievement in patients with heterozygous familial hypercholesterolemia at Groote Schuur Hospital: Minority at target despite large reductions in LDL-C.
    van Delden XM; Huijgen R; Wolmarans KH; Brice BC; Barron JK; Blom DJ; Marais AD
    Atherosclerosis; 2018 Oct; 277():327-333. PubMed ID: 30270067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mipomersen and lomitapide: Two new drugs for the treatment of homozygous familial hypercholesterolemia.
    Gouni-Berthold I; Berthold HK
    Atheroscler Suppl; 2015 May; 18():28-34. PubMed ID: 25936301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics and management of 1093 patients with clinical diagnosis of familial hypercholesterolemia in Greece: Data from the Hellenic Familial Hypercholesterolemia Registry (HELLAS-FH).
    Rizos CV; Elisaf MS; Skoumas I; Tziomalos K; Kotsis V; Rallidis L; Garoufi A; Athyros VG; Skalidis E; Kolovou G; Koutagiar I; Papagianni M; Antza C; Katsiki N; Ganotakis E; Liberopoulos EN
    Atherosclerosis; 2018 Oct; 277():308-313. PubMed ID: 30270064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Editorial Commentary: What Determines the Risk of Cardiovascular Disease in Familial Hypercholesterolemia?
    Brunham LR; Mancini GBJ
    Trends Cardiovasc Med; 2021 May; 31(4):216-217. PubMed ID: 32407995
    [No Abstract]   [Full Text] [Related]  

  • 16. Changes in carotid stiffness in patients with familial hypercholesterolemia treated with Evolocumab®: A prospective cohort study.
    Di Minno MND; Gentile M; Di Minno A; Iannuzzo G; Calcaterra I; Buonaiuto A; Di Taranto MD; Giacobbe C; Fortunato G; Rubba POF
    Nutr Metab Cardiovasc Dis; 2020 Jun; 30(6):996-1004. PubMed ID: 32402582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel therapies for treating familial hypercholesterolemia.
    Bandeali SJ; Daye J; Virani SS
    Curr Atheroscler Rep; 2014 Jan; 16(1):382. PubMed ID: 24293346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evinacumab for Homozygous Familial Hypercholesterolemia.
    Raal FJ; Rosenson RS; Reeskamp LF; Hovingh GK; Kastelein JJP; Rubba P; Ali S; Banerjee P; Chan KC; Gipe DA; Khilla N; Pordy R; Weinreich DM; Yancopoulos GD; Zhang Y; Gaudet D;
    N Engl J Med; 2020 Aug; 383(8):711-720. PubMed ID: 32813947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Very high-risk familial hypercholesterolaemia patients in real life: The remaining gap in achieving the current LDL-C targets despite the use of PCSK9 inhibitors.
    Rallidis LS; Liberopoulos EN; Vlachopoulos C; Skoumas I; Kolovou G; Anastasiou G; Dima I; Tousoulis D; Iliodromitis E
    Atherosclerosis; 2020 Sep; 309():67-69. PubMed ID: 32859385
    [No Abstract]   [Full Text] [Related]  

  • 20. High burden of recurrent cardiovascular events in heterozygous familial hypercholesterolemia: The French Familial Hypercholesterolemia Registry.
    Béliard S; Boccara F; Cariou B; Carrié A; Collet X; Farnier M; Ferrières J; Krempf M; Peretti N; Rabès JP; Varret M; Vimont A; Charrière S; Bruckert E;
    Atherosclerosis; 2018 Oct; 277():334-340. PubMed ID: 30270068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.